Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccination for Esophageal Squamous Cell Carcinoma
NCT00995358Phase 2Unknown
- Sponsor
- University of Yamanashi
- Start
- Nov 2008
- Primary completion
- Oct 2010
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TTK peptide in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by University of Yamanashi. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
TTK peptide
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT00995358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00995358.